Human Genome Epidemiology Literature Finder
Rare Diseases
|
Records 1 - 30 (of 443 Records) |
| Query Trace: Myelofibrosis[original query] |
|---|
| The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease's phenotype. Frontiers in oncology 2023 9 13 1224590. Patryk Sobieralski, Bartosz Was?g, Aleksandra Leszczy?ska, Monika ?uk, Maria Bieniaszews |
| U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood cancer journal 2023 9 13 (1): 149. Talha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, James M Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B Alkhateeb, David Viswanatha, Rong He, Mithun Shah, Cecilia Arana Yi, Mark R Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M Patna |
| The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis. Frontiers in oncology 2023 8 13 1190305. Helna Pettersson, Jenni Adamsson, Peter Johansson, Staffan Nilsson, Lars Palmqvist, Björn Andréasson, Julia A |
| The Clinical Impact of JAK2V617F allele burden in Philadelphia-negative Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology 2023 8 . ?pek Yönal-Hindilerden, Ezgi ?ahin, Fehmi Hindilerden, Aynur Da?lar-Aday, Meliha Nalça |
| Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing. Cancers 2023 8 15 (15): . Marta Garrote, Mónica López-Guerra, Eduardo Arellano-Rodrigo, María Rozman, Sara Carbonell, Francesca Guijarro, Marta Santaliestra, Ana Triguero, Dolors Colomer, Francisco Cervantes, Alberto Álvarez-Larr |
| Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN. Frontiers in genetics 2023 7 14 1198834. Jin Zhang, Kefeng Shen, Min Xiao, Jinjin Huang, Jin Wang, Yaqin Wang, Zhenya Ho |
| High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis. Journal of applied genetics 2023 7 . Zuzanna Kandu?a, Micha? Janowski, Barbara Wi?ckowska, Edyta Paczkowska, Aleksandra Mroczkowska-B?karciak, Marta Sobas, Krzysztof Lewandows |
| [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2023 6 44 (4): 276-283. X Yan, T J Qin, B Li, S Q Qu, L J Pan, F H Li, N N Liu, Z J Xiao, Z F |
| The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. British journal of haematology 2023 5 . Mark Gurney, Ismahene Chekkaf, Anmol Baranwal, Rami Basmaci, Bahga Katamesh, Patricia Greipp, James M Foran, Talha Badar, Abhishek A Mangaonkar, Kebede H Begna, Naseema Gangat, Mrinal M Patnaik, Mark R Litzow, Mithun V Shah, David S Viswanatha, Rong He, Hassan B Alkhateeb, Aref Al-Ka |
| Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms. Molecular biology reports 2023 5 . It?r ?irino?lu Demiriz, Mehmet Hanifi Kazanci, Esra Menfaatli, Davoud Jafari-Gharabaghlou, Nosratollah Zargha |
| JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients. Hematology/oncology and stem cell therapy 2023 4 16 (3): 303-314. Shires Karen L, Rust Adriana J, Harryparsad Rushil, Coburn Justin A, Gopie Ruth |
| Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis. Advances in experimental medicine and biology 2023 4 1408 273-290. Sun?ica Kapor, Sanja Mom?ilovi?, Slobodan Kapor, Slavko Mojsilovi?, Milica Radojkovi?, Milica Apostolovi?, Branka Filipovi?, Mirjana Goti?, Vladan ?oki?, Juan F Santiban |
| Exploration of the role of NKG2D ligands MICA and MICB in JAK2 V617F-positive myeloproliferative neoplasms. HLA 2023 4 . Ivanova Milena, Tsvetkova Gergana, Lessichkova Spaska, Gesheva Nevena, Hadjiev Evgueniy, Shivarov Veliz |
| Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood 2023 3 . Gagelmann Nico, Badbaran Anita, Salit Rachel B, Schroeder Thomas, Gurnari Carmelo, Pagliuca Simona, Panagiota Victoria, Rautenberg Christina, Cassinat Bruno, Thol Felicitas R, Wolschke Christine, Robin Marie, Heuser Michael, Rubio Marie-Thérèse, Maciejewski Jaroslaw P, Reinhardt Hans Christian, Scott Bart L, Kröger Nicola |
| CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study. Cancers 2023 3 15 (5): . Messerich Nora-Medea, Uda Narasimha Rao, Volken Thomas, Cogliatti Sergio, Lehmann Thomas, Holbro Andreas, Benz Rudolf, Graf Lukas, Gupta Vikas, Jochum Wolfram, Demmer Izadora, Rao Tata Nageswara, Silzle Tobi |
| Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan. American journal of clinical pathology 2023 3 . Kuo Ming-Chung, Chuang Wen-Yu, Chang Hung, Lin Tung-Huei, Wu Jin-Hou, Lin Tung-Liang, Ou Che-Wei, Hung Yu-Shin, Huang Ting-Yu, Huang Ying-Jung, Wang Po-Nan, Shih Lee-Yu |
| Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation. Transplantation and cellular therapy 2024 8 . Nico Gagelmann, Claudia Schuh, Robert Zeiser, Matthias Stelljes, Wolfgang Bethge, Gerald Wulf, Daniel Teschner, Stefan Klein, Eva Wagner-Drouet, Edgar Jost, Peter Dreger, Sarah Flossdorf, Nicolaus Krög |
| Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis. Leukemia 2024 8 . Irene Pastor-Galán, Arturo Pereira, Eduardo Arellano-Rodrigo, Iván Martín, Adrián Mosquera-Orgueira, María-Teresa Gómez-Casares, Alberto Hernández-Sánchez, Francisca Ferrer-Marín, Elvira Mora, Patricia Velez, Rosa Ayala, Anna Angona, Natalia de Las Heras, Elena Magro, María-Isabel Mata-Vázquez, María-Laura Fox, Sonia González de Villambrosía, María-José Ramírez, Ana García, Valentín García-Gutiérrez, Amparo Cáceres, María-Antonia Durán, María-Alicia Senín, José-María Raya, José Antonio González, Beatriz Cuevas, Blanca Xicoy, Marta Garrote, Blanca Ferrer, Manuel Pérez-Encinas, Jesús María Hernández-Rivas, Beatriz Bellosillo, Alberto Álvarez-Larrán, Juan Carlos Hernández-Bolu |
| Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study. Cancer 2024 7 . Francesca Palandri, Elena M Elli, Erika Morsia, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Massimiliano Bonifacio, Mirko Farina, Bruno Martino, Giovanni Caocci, Novella Pugliese, Alessia Tieghi, Monica Crugnola, Gianni Binotto, Francesco Cavazzini, Elisabetta Abruzzese, Alessandra Iurlo, Alessandro Isidori, Costanza Bosi, Veronica Guglielmana, Marta Venturi, Alessandra Dedola, Michele Loffredo, Gabriele Fontana, Andrea Duminuco, Alessia Moioli, Luca Tosoni, Emilia Scalzulli, Daniele Cattaneo, Roberto M Lemoli, Daniela Cilloni, Monica Bocchia, Fabrizio Pane, Florian H Heidel, Nicola Vianelli, Michele Cavo, Giuseppe A Palumbo, Filippo Branzanti, Massimo Brecc |
| [Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model]. Zhonghua yi xue za zhi 2024 7 104 (25): 2336-2341. J Y Ma, Y H Zhang, G S Teng, C X Du, H Q Zhang, Y Wang, Y Q Li, Y F Duan, Y Zhou, Z H Shao, J B |
| Prevalence and clinicopathological features of driver gene mutations profile in BCR: ABL1 negative classical myeloproliferative neoplasm-A single-center study from North India. Indian journal of pathology & microbiology 2024 5 . Khaliqur Rahman, Seema Biswas, Akhilesh Sharma, Kusum Gupta, Dinesh Chandra, Manish K Singh, Ruchi Gupta, Ashish Mishra, Sanjeev Kumar, Anshul Gupta, Faheema Hasan, Soniya Nityanand, Rajesh Kahsy |
| Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2024 5 125 159-166. Shirong Wen, Wenxiao Zhang, Yiping Fei, Ke Guan, Hui Zhao, Peng Song, Xiangmei Ye, Yujun P |
| Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic Burden, and Thrombosis. Turkish journal of haematology : official journal of Turkish Society of Haematology 2024 5 . Elif Ümit, Mehmet Baysal, Hakk? Onur K?rk?zlar, Ahmet Muzaffer Dem |
| Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis. Annals of hematology 2024 4 . Chih-Cheng Chen, Justin L Chen, Alex Jia-Hong Lin, Lennex Hsueh-Lin Yu, Hsin-An H |
| Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study. Leukemia 2024 10 . Yu-Hung Wang, Chao-Hung Wei, Chien-Chin Lin, Carmelo Gurnari, Hussein Awada, Lina Benajiba, Rafael Daltro de Oliveira, Juliette Soret-Dulphy, Bruno Cassinat, Andrius Zucenka, Adrián Mosquera Orgueira, Chang-Tsu Yuan, Sze-Hwei Lee, Chi-Yuan Yao, Kristian Gurashi, Hsin-An Hou, Kiran Batta, Manuel Mateo Pérez Encinas, Wen-Chien Chou, Jaroslaw P Maciejewski, Daniel H Wiseman, Jean-Jacques Kiladjian, Hwei-Fang Ti |
| Features and allele frequency of JAK2 Exon 12-mutated polycythemia vera in comparison with JAK2V617F-mutated disease. Archives of medical research 2024 10 56 (2): 103109. Chin-Hsuan Chuang, Ming-Chung Kuo, Jin-Hou Wu, Tung-Liang Lin, Po-Nan Wang, Yueh-Shih Chang, Tung-Hui Lin, Ting-Yu Huang, Yu-Shin Hung, Hsiao-Wen Kao, Che-Wei Ou, Hung Chang, Lee-Yung Sh |
| The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis. American journal of hematology 2024 1 . Alberto Hernández-Sánchez, Ángela Villaverde-Ramiro, Eduardo Arellano-Rodrigo, Marta Garrote, Iván Martín, Adrián Mosquera-Orgueira, María-Teresa Gómez-Casares, Francisca Ferrer-Marín, Esperanza Such, Patricia Velez, Rosa Ayala, Anna Angona, Natalia de Las Heras, Elena Magro, María-Isabel Mata-Vázquez, María-Laura Fox, Sonia González de Villambrosía, María-José Ramírez, Ana García, Valentín García-Gutiérrez, Amparo Cáceres, María-Antonia Durán, Alicia Senín, José-María Raya, José Antonio González, Beatriz Cuevas, Blanca Xicoy, Manuel Pérez-Encinas, Beatriz Bellosillo, Alberto Álvarez-Larrán, Jesús María Hernández-Rivas, Juan Carlos Hernández-Boluda, |
| CALR mutation burden in essential thrombocythemia and disease outcome. Blood 2024 1 . Paola Guglielmelli, Natasha Szuber, Naseema Gangat, Giulio Capecchi, Chiara Maccari, Michaël Harnois, Omer Karrar, Maymona Abdelmagid, Manjola Balliu, Elena Nacca, Alessandro Atanasio, Ilaria Sestini, Audrey Desilets, Giuseppe Gaetano Loscocco, Giada Rotunno, Lambert Busque, Ayalew Tefferi, Alessandro Maria Vannucc |
| One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood cancer journal 2024 1 14 (1): 11. Naseema Gangat, Omer Karrar, Aref Al-Kali, Kebede H Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Animesh Pardanani, Curtis A Hanson, Rhett P Ketterling, Ayalew Teffe |
| One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood cancer journal 2024 1 14 (1): 10. Giuseppe G Loscocco, Francesca Gesullo, Giulio Capecchi, Alessandro Atanasio, Chiara Maccari, Francesco Mannelli, Alessandro M Vannucchi, Paola Guglielmel |
- Page last reviewed:Feb 1, 2024
- Content source: